NCT06211465|Completed
Cardiovascular And Metabolic Risk After Arthroplasty
CAMERA
Loading search results
CAMERA
Sponsor study identifier
observational
152
1 country
1
Study Start
March 1, 2014
Actual (reported)Primary Completion
January 2023
Actual (reported)Study Completion
April 2023
Actual (reported)Osteoarthritis is a chronic joint disease that lacks curative therapy. Epidemiological studies show increase in the burden of disease. Total joint arthroplasty is one of the best treatment options for end-stage osteoarthritis. However, the specific effects of total joint arthroplasty on cardiovascular risk and metabolic profile are largely unknown. The aim of this project is to elucidate how hip and knee total joint arthroplasty impacts cardiovascular risk and metabolomic profile in comparison with general population. We hypothesize that arthroplasty decreases pain, systemic inflammation levels and increases functional status that all lead to decreased metabolic and cardiovascular risk.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 1, 2014
Actual (reported)December 30, 2020
Actual (reported)January 2023
Actual (reported)April 2023
Actual (reported)January 18, 2024
Actual (reported)Aortic pulse wave velocity at 5 years after arthroplasty
5 years after the beginning of study for control group; measurements are done using the Sphygmocor device.
5 years
Changes in low-molecular weight metabolites
5 years
Oxidative stress index
5 years
Leptin levels
Patients with end-stage osteoarthritis (OA), who were eligible for total joint arthroplasty in Tartu University Hospital. Exclusion criteria: posttraumatic OA, infectious or endocrine arthropathy, acute or chronic inflammatory disease, malignancies, end-stage renal impairment (eGFR \< 60ml/min/1.73m2), dysrhythmias, clinically relevant heart failure, heart valve-disease, diabetes.
Gender and age matched control group, who is recruited from the general practitioner (GP) list and who are from the same geographical regions as the cases. Excluding criteria: acute or chronic inflammatory disease, GP visitation due to hip or knee problems, persistent knee or hip pain, diabetes, symptomatic coronary disease, dysrhythmias, cerebrovascular or peripheral artery disease, malignancy or renal impairment.
Hip or knee total joint arthroplasty
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with primary osteoarthritis
University of Tartu
Tartu, Tartu, 51014, Estonia
Serum and plasma
Kaspar Tootsi, PhD, MD
University of Tartu
Kadri Vilba, MD
University of Tartu
Aare Märtson, PhD, MD
University of Tartu
Jaak Kals, PhD, MD
University of Tartu
152 participants (actual enrollment reported by the registry).
First Submitted
December 30, 2020
First Posted
January 18, 2024
Study Start
March 1, 2014
Actual (reported)Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA)
5 years
Metabolic syndrome risk score
5 years
Harris Hip score or Hospital for Special Surgery Knee score
5 years
Contact the study team to confirm eligibility.
Primary Completion
January 2023
Actual (reported)Study Completion
April 2023
Actual (reported)Last Updated
January 18, 2024
Record last verified: 2024-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: